Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.80 |
---|---|
High | 8.00 |
Low | 7.80 |
Bid | 8.00 |
Offer | 8.30 |
Previous close | 7.85 |
Average volume | 0.00 |
---|---|
Shares outstanding | 309.54m |
Free float | 129.11m |
P/E (TTM) | -- |
Market cap | 2.70bn USD |
EPS (TTM) | -0.6224 USD |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Press releases
- Amneal Reports Third Quarter 2024 Financial Results
- Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
- Amneal to Report Third Quarter 2024 Results on November 8, 2024
- Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
- Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
- Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
- Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
More ▼